NLS Pharmaceutics AG reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was USD 7.61 million compared to USD 8.64 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.54 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1393 USD | -1.55% | +0.94% | -76.39% |
08/04 | Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors | CI |
03/04 | NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-76.39% | 6.57M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NLSP Stock
- News NLS Pharmaceutics Ltd.
- NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023